HUP0202734A2 - Pegilezett alfa-interferon és egy CCR5 antagonista kombinációjának alkalmazása HIV-terápiára - Google Patents

Pegilezett alfa-interferon és egy CCR5 antagonista kombinációjának alkalmazása HIV-terápiára

Info

Publication number
HUP0202734A2
HUP0202734A2 HU0202734A HUP0202734A HUP0202734A2 HU P0202734 A2 HUP0202734 A2 HU P0202734A2 HU 0202734 A HU0202734 A HU 0202734A HU P0202734 A HUP0202734 A HU P0202734A HU P0202734 A2 HUP0202734 A2 HU P0202734A2
Authority
HU
Hungary
Prior art keywords
hiv
pegylated
ccr5 antagonist
interfron
alfa
Prior art date
Application number
HU0202734A
Other languages
English (en)
Inventor
Mark A. Laughlin
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0202734A2 publication Critical patent/HUP0202734A2/hu
Publication of HUP0202734A3 publication Critical patent/HUP0202734A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgya pegilezett alfa-interferon és egy CCR5 antagonistaalkalmazása HIV-1-fertőzött, illetve pegilezett alfa-interferon, egyCCRS antagonista, ribavirin és a HAART hatóanyagai alkalmazása a HIV-1és HCV által együttesen fertőzött páciensek kezelésére szolgálógyógyszerkészítmény előállítására. A kezelés pegilezett alfa-interferon terápiásan hatásos mennyiségének, egy CCR5 antagonistaterápiásan hatásos mennyiségének, valamint adott esetben ribavirin ésmás anti-HIV-1 hatóanyagok terápiásan hatásos, a HIV-1-RNS, illetve aHCV-RNS csökkentéséhez elegendő mennyiségének egymással összefüggőbeadásából áll. Ó
HU0202734A 1999-05-04 2000-05-01 Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy HUP0202734A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04
PCT/US2000/011634 WO2000066141A2 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Publications (2)

Publication Number Publication Date
HUP0202734A2 true HUP0202734A2 (hu) 2002-12-28
HUP0202734A3 HUP0202734A3 (en) 2003-11-28

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202734A HUP0202734A3 (en) 1999-05-04 2000-05-01 Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy

Country Status (21)

Country Link
EP (1) EP1175224B1 (hu)
JP (1) JP2002543144A (hu)
CN (1) CN1349408A (hu)
AR (1) AR023824A1 (hu)
AT (1) ATE289516T1 (hu)
AU (1) AU776541B2 (hu)
BR (1) BR0010593A (hu)
CA (1) CA2365900A1 (hu)
DE (1) DE60018273T2 (hu)
ES (1) ES2238277T3 (hu)
HK (1) HK1039278B (hu)
HU (1) HUP0202734A3 (hu)
MX (1) MXPA01011116A (hu)
MY (1) MY127670A (hu)
NO (1) NO328679B1 (hu)
NZ (1) NZ514519A (hu)
PE (1) PE20010283A1 (hu)
PT (1) PT1175224E (hu)
TW (1) TWI289454B (hu)
WO (1) WO2000066141A2 (hu)
ZA (1) ZA200108870B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
JPWO2004092136A1 (ja) * 2003-04-18 2006-07-06 小野薬品工業株式会社 含窒素複素環化合物およびその用途
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
DE602005002673T2 (de) 2004-04-29 2008-07-24 F. Hoffmann-La Roche Ag Nukleotidsequenzvariation im Gen NS5A als Marker
MX2007002886A (es) 2004-09-13 2007-05-16 Ono Pharmaceutical Co Derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo.
KR20070107085A (ko) * 2005-02-23 2007-11-06 쉐링 코포레이션 케모카인 수용체의 억제제로서 유용한 피페리디닐 피페라진유도체
EP1889622A4 (en) 2005-05-31 2009-12-23 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
PL1942108T3 (pl) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Związek zawierający grupę zasadową i jego zastosowanie
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
CN101443322A (zh) 2006-03-10 2009-05-27 小野药品工业株式会社 含氮杂环衍生物及含有该衍生物作为活性成分的药物
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP2780015B1 (en) 2011-11-18 2017-01-04 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
US10272143B2 (en) * 2014-01-08 2019-04-30 Immunovative Therapies Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos

Also Published As

Publication number Publication date
CA2365900A1 (en) 2000-11-09
AU4681500A (en) 2000-11-17
WO2000066141A3 (en) 2001-02-08
PT1175224E (pt) 2005-07-29
ZA200108870B (en) 2003-03-26
AR023824A1 (es) 2002-09-04
EP1175224A2 (en) 2002-01-30
TWI289454B (en) 2007-11-11
DE60018273D1 (de) 2005-03-31
ATE289516T1 (de) 2005-03-15
WO2000066141A2 (en) 2000-11-09
BR0010593A (pt) 2002-02-13
HK1039278B (zh) 2005-06-30
CN1349408A (zh) 2002-05-15
NO20015367D0 (no) 2001-11-02
JP2002543144A (ja) 2002-12-17
PE20010283A1 (es) 2001-03-16
EP1175224B1 (en) 2005-02-23
MXPA01011116A (es) 2002-06-04
NO328679B1 (no) 2010-04-26
DE60018273T2 (de) 2005-08-18
ES2238277T3 (es) 2005-09-01
HK1039278A1 (en) 2002-04-19
NZ514519A (en) 2003-07-25
MY127670A (en) 2006-12-29
NO20015367L (no) 2002-01-03
AU776541B2 (en) 2004-09-16
HUP0202734A3 (en) 2003-11-28

Similar Documents

Publication Publication Date Title
HUP0202734A2 (hu) Pegilezett alfa-interferon és egy CCR5 antagonista kombinációjának alkalmazása HIV-terápiára
HUP0100092A2 (hu) Kombinációs terápia kimutatható HCV-RNS eradikációjára krónikus hepatitis-C fertőzött betegekben
HUP0103423A2 (hu) Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
HUP0500558A2 (hu) Alacsony dózisú entecavir formuláció és eljárás előállítására
RU2329050C2 (ru) Комбинация ингибиторов цитохром-р450-зависимых протеаз
HUP0000299A1 (hu) Késleltetett hatóanyag-leadású gyógyszerkészítmények
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
HUP0302334A2 (hu) Vírusellenes hatású nukleozid-vegyületek prekurzorjai, valamint e vegyületek alkalmazása gyógyászati készítmények előállítására
JP2009504157A5 (hu)
YU27203A (sh) Pirazol derivati za tretiranje virusnih oboljenja
WO2006044968A3 (en) Combination therapy for treating viral infections
WO2002034284A3 (en) Methods of therapy for hiv infection
HUP0400553A2 (hu) Gyógyászati készítmények
HUP0300354A2 (hu) HIV immunadjuváns terápia
RU2005131578A (ru) Аплидин для лечения множественной миеломы
WO2006033971A3 (en) Starch-pomegranate juice coomplex as an hiv entry inhibitor and topical microbicide
HUP0204324A2 (en) Use of fsh for preparation of pharmaceutical composition suitable for treating infertility
HUP0301451A2 (hu) CGMP PDE5 inhibitorok alkalmazása perifériás érbetegségek, perifériás neuropátiák és autonóm neuropátiák kezelésére szolgáló gyógyszerkészítmények elżállítására
DK1143976T3 (da) Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
Chapman et al. Clinical potential of a new HIV protease inhibitor
Scheibel Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, MD Interview by John S. James
Colvin HIV resistance: the new enemy
Mascolini Protease inhibitor update: treatment combination strategies

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees